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The association between social support and medication adherence has been studied in several 
chronic diseases. However, this association has not been extensively explored in patients with 
rheumatoid arthritis (RA), especially with valid and objective measures. The purpose of this 
study was to examine the association between social support and medication adherence in adults 
with RA using a valid and reliable social support questionnaire, the Interpersonal Support 
Evaluation List (ISEL), and the Medication Event Monitoring System (MEMS) to objectively 
measure medication adherence of RA drugs. A cross-sectional, descriptive, correlational design 
was used for this secondary analysis of data from a randomized controlled trial of a behavioral 
intervention to improve medication adherence in patients with RA. The parent study used 
convenience sampling, and a total of 567 subjects were included in this secondary analysis. At 
baseline, the subjects completed a sociodemographic questionnaire and the ISEL. Then the 
subjects were instructed to use the MEMS cap for 30 days. Multivariate logistic regression 
analyses were used to examine which of the four ISEL subscale scores (tangible, appraisal, self-
esteem, and belonging) best predicted each of the adherence measures (dose adherence, days 
adherence, and on-time adherence). No social support subscale significantly predicted days 
adherence. Tangible social support was a significant predictor of dose adherence (OR=1.082, 
95% CI=1.008 - 1.162). For on-time adherence, self-esteem social support was a significant 
predictor (OR=0.942, 95% CI=0.893 - 0.994). These results may be due to controlling for the 
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effect of other social support subscale measures that may be related to alternate variables 
affecting the associations between the adherence and social support. A further study examining 
these variables is recommended for a greater understanding of the role of social support on 
medication adherence in persons with RA. 
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1.0  INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease in which joint damage occurs when the 
immune system mistakenly recognizes the joint structures as foreign (Ruderman & Tambar, 
2013). This process creates inflammation that causes thickening of the tissue lining the joints, 
and results in pain, stiffness, swelling and limited mobility and function of these joints 
(Ruderman & Tambar, 2013). The most commonly affected joints are the small joints in the 
hands and feet (Ruderman & Tambar, 2013). 
About 1.5 million people in the United States are affected by RA, with about 75% of 
these being women (Dugowson et al., 1991). Currently, 1-3% of women have a chance of being 
diagnosed with RA throughout their lifetime. Although this disease commonly begins between 
30 and 60 years of age, it can start at any age and cause chronic disability of the joints 
(Ruderman & Tambar, 2013). Over time, permanent joint deformity can occur; therefore, early 
diagnosis, a treat-to-target strategy, and adherence to the medication regimen to control RA are 
recommended. 
RA is associated with other medical co-morbidities as well. The primary co-morbidity for 
people with RA is cardiovascular disease (CVD), particularly ischemic heart disease (Wolfe et 
al., 1994). It is unclear whether the risk of CVD is due to RA, the risk factors associated with 
RA, such as hypertension and higher likelihood of being a smoker, or the effects of the drugs 
used to treat RA (Wolfe et al., 1994). The second most common co-morbidity is infection, most 
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frequently tuberculosis, which is one of the primary causes of death among people with RA and 
may be responsible for one-quarter of deaths among this population. Other co-morbidities 
associated with RA are mental health problems and lymphoproliferative malignancies, such as 
leukemia and multiple myeloma. A high prevalence of anxiety and depression has been 
documented as well (Dickens, McGowan, Clark-Carter, & Creed, 2002). 
Not only is the physical disability from RA debilitating, but the financial toll is 
significant. As with any illness, there are direct and indirect costs associated with RA. A study of 
direct costs, such as medical costs, among people with RA found an average cost of $2,085 per 
person annually (Kawatkar et al., 2012). In addition, patients with RA are six times more likely 
than people without arthritis to incur other medical expenses independent of RA. The age-
adjusted indirect costs, such as non-medical expenditures, for a person with RA are on average 
$1,212 annually (Simons, Rosenblatt, & Trivedi, 2012). Regarding employment, people with RA 
are more likely to have difficulty finding a job, change occupations, lose their jobs, reduce work 
hours, and retire early (Gabriel, Crowson, Campion, & O'Fallon, 1997). These factors would put 
additional financial strain on patients with RA. 
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2.0  BACKGROUND 
The World Health Organization (WHO) has a model that predicts adherence to medical regimen 
of long-term therapies in various illnesses. This model has five sets of factors that interplay to 
affect adherence and include the following: socioeconomic-related, healthcare team/health 
system-related, condition-related, therapy-related, and patient-related (Sabate, 2003). The 
socioeconomic-related factor in this model of adherence includes social support. The association 
of social support with adherence has been studied in several chronic disorders. However, the 
association of social support with medication adherence has not been explored extensively in 
patients with RA (Van den Bemt, Van den Ende, & Zwikker, 2012). Therefore in the proposed 
study, the association between social support and medication adherence posited by this model 
was examined in patients with RA. 
Medication adherence is defined as the extent to which a patient’s behavior, with respect 
to taking medication, corresponds with agreed recommendations from a healthcare provider 
(Sabate, 2003). Therapy for RA has greatly improved in the past 30 years. The current 
management of RA is not curative, but can significantly reduce the progression of joint damage 
and provide good relief of symptoms, especially with early aggressive treatment. 
Pharmacotherapy often consists of disease-modifying anti-rheumatic drugs (DMARDs), 
corticosteroids, and some biologic response modifier agents (Van den Bemt, et al., 2012). 
Medication nonadherence has negative consequences, such as increased disease flares and 
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disability. Adherence rates to prescribed medication regimens in people with RA are low, 
varying from 30-80%, depending on how adherence is measured and various patient 
characteristics (van den Bemt et al., 2012). Achieving greater adherence to the therapy could 
improve efficacy of the medication treatments, decrease disability, and reduce health care costs 
associated with the disease. 
Social support is a patient characteristic that may affect patients’ management of their 
health problems. According to Sabate (2003), social support is described as informal or formal 
support received by patients from other members of their community. Social support can be 
differentiated into functional and structural social support. There are three types of functional 
social support, which are practical, emotional, and family cohesiveness. Structural social support 
is described by marital status and living arrangement of adults (DiMatteo, 2004). Social support 
networks are known to buffer disease-related distress and improve quality of life in patients with 
RA by enhancing their ability to cope (Elliot, 2008). Although social support has been found to 
improve psychological well-being in patients with RA (Treharne, Lyons, & Kitas, 2004), less is 
known about the association between social support and medication adherence in patients with 
RA. 
A few studies have examined the association between social support and medication 
adherence in patients with RA. A study completed in Taiwan by Chen and Wang (2007) used a 
cross-sectional design with 115 participants. Social support was measured using a 15-item social 
support scale designed by Wang (2000) to determine the degree of social support perceived by 
the participants. The social support subscales had Cronbach’s alpha coefficients of .78 for 
emotional support, .74 for cognitive support, .60 for informational support, and .52 for tangible 
support. The Cronbach’s alpha coefficient of the overall social support scale in the study was .86. 
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Medication adherence was measured by using the Self-Care Behavior Scale of RA patients 
(SCBS), which was adapted from a scale used in a study by Peng (1997). The results showed that 
patients with RA who have a higher level of social support have better self-care behavior, 
including medication adherence (r=0.19, p=.0469). 
Wong and Mulherin (2007) conducted a prospective cohort study examining medication 
beliefs and psychosocial factors shortly after starting DMARD therapy and one year later. The 
sample of 68 patients with RA was recruited from a rheumatology department in a hospital in 
England. Social support was measured by using a Significant Others Scale Questionnaire, and 
medication adherence was assessed via patient self-report. The data were collected in a semi-
structured interview, and a stepwise logistic regression model was applied to find the predictive 
value of medication beliefs and psychosocial factors, such as social support, on early 
discontinuation of DMARD therapy. The results indicated that social support was not significant 
in predicting medication adherence (regression coefficient not reported, p≥.05). 
Another study conducted in England by Treharne et al. (2004) investigated the 
associations of several psychosocial factors including social support on medication adherence in 
85 patients with RA. In this cross-sectional study, social support was evaluated using the Social 
Support Questionnaire, and medication adherence was assessed using the Compliance 
Questionnaire. These results demonstrated that social support satisfaction (r=-0.15, p≥.05) and 
number in the social support network (r=0.03, p≥.05) were not statistically significantly related 
to medication adherence. 
Finally, a study led by Brus, van de Laar, Taal, Rasker, and Wiegman (1999) in the 
Netherlands investigated the relationship of social support on medication adherence in patients 
with RA. This study used a descriptive correlational design with secondary analysis of data from 
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a randomized, controlled, assessor-blinded clinical trial of patient education in a sample of 65 
patients. Medication adherence was measured from 3 to 6 months via a pill counting procedure 
on sulphasalazine by the assessor. High adherence was defined as greater than or equal to 80%, 
and low adherence was defined as less than 80%. Adherence was comparable between the two 
groups in this trial so the data were combined. Perceived social support was measured by a single 
item on a 5-point scale at 3 months. The correlation between medication adherence with 
sulphasalazine treatment and perceived social support was not significant (r=0.20, p≥.05). In the 
logistic regression analysis for medication adherence with sulphasalazine treatment, perceived 
social support was not a significant predictor (p=0.15, OR and 95% CI were not reported). 
To summarize, although the study by Chen and Wang (2007) found a significantly 
positive relationship between social support and medication adherence, the other three studies 
did not, which suggests that current evidence is inconclusive. In addition, all of these studies 
were conducted outside of the United States and had several limitations, including small sample 
sizes, a variety of social support measures, and self-report questionnaires or pill counts to 
measure medication adherence, which may not provide the most accurate information. 
In this study, we addressed these gaps by using a large sample, measuring social support 
with the valid and reliable Interpersonal Support Evaluation List (ISEL) (Cohen, 1985), and 
assessing medication adherence objectively with the Medication Event Monitoring System 
(MEMS). MEMS data were used to compute percentage of prescribed administrations/doses 
taken (dose adherence), percentage of days with the prescribed number of administrations/doses 
(days adherence), and percentage of days with the prescribed number of administrations/doses 
and optimal inter-dose intervals (on-time adherence). 
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2.1 PURPOSE 
The purpose of this secondary analysis was to examine the association between social support 
and medication adherence in adults with RA. 
The research questions were: 
1) Is tangible support related to (a) dose adherence, (b) days adherence, and (c) on-time 
adherence? 
2) Is appraisal support related to (a) dose adherence, (b) days adherence, and (c) on-time 
adherence? 
3) Is self-esteem support related to (a) dose adherence, (b) days adherence, and (c) on-
time adherence? 
4) Is belonging support related to (a) dose adherence, (b) days adherence, and (c) on-time 
adherence? 
5) Is total support related to (a) dose adherence, (b) days adherence, and (c) on-time 
adherence? 
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3.0  METHODS 
3.1 DESIGN 
This secondary analysis used a cross-sectional, descriptive, correlational design with data from a 
randomized controlled trial of a behavioral intervention to improve medication adherence in 
patients with RA. Permission for the secondary analysis was granted by the Principal 
Investigator, Dr. Jacqueline Dunbar-Jacob (NIH, R01 NR04554). University of Pittsburgh 
Human Research Protection Office approved this study. 
3.2 SAMPLE AND SETTING 
Convenience sampling was used in the parent study to obtain the study sample. The data in the 
parent study were collected from a community-based sample from 11/01/1999 to10/31/2003. The 
parent study screened 663 adults with RA. This study used data on 567 adults with RA who were 
enrolled in the parent study and had complete data on the social support and medication 
adherence variables. The nominal scaled categorical variables, such as sex, race, marital status, 
and employment status, and the continuous type variables, such as age and number of years of 
formal education, of subjects with complete data (n=567) and missing data (n=96) were 
compared and no significant differences were found. Therefore, for this study the subjects with 
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only complete data were included in the statistical analyses and were deemed representative of 
the full sample of the parent study. 
3.3 MEASURES 
The Interpersonal Support Evaluation List (ISEL) by Cohen (1985) was used to measure social 
support for this study. The ISEL consists of 40 statements regarding the perceived availability of 
social support. The items are half positive and half negative statements about social relationships 
in order to counterbalance for desirability (Cohen, 1985). The items were developed based on the 
domains of supportive social resources that could potentially facilitate coping with stressful 
events. Participants rate the statements as “definitely false,” “probably false,” “probably true,” or 
“definitely true” about themselves. Each item is scored from 0 to 3. 
The items on the ISEL are categorized into four 10-item subscales that comprise the 
separate components of social support. The “tangible” subscale captures the perceived 
availability of material aid. The “appraisal” subscale is the perceived availability of a person to 
speak to about one’s problems. The “self-esteem” subscale is the perceived availability of a 
positive comparison when one compares himself or herself to others. Lastly, the “belonging” 
subscale is the perceived availability of people with whom one can do things (Cohen, 1985). The 
possible range for each subscale score is 0 to 30 with higher scores indicating greater social 
support. The possible range for the total score is 0 to 120. The ISEL is a widely used, valid and 
reliable instrument with internal consistency reliability of α=0.88 to 0.90 for the total score. 
Subscale alpha coefficients were 0.73 to 0.81 for tangible, 0.70 to 0.82 for appraisal, 0.62 to 0.73 
for self-esteem, and 0.73 to 0.78 for belonging (Cohen, 1985). In the parent study, the 
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Cronbach’s alpha coefficient was 0.94 for the total score, and the subscale Cronbach’s alpha 
coefficients were 0.83 for tangible, 0.88 for appraisal, 0.79 for self-esteem, and 0.85 for 
belonging. Test-retest reliability based on Pearson correlation coefficients for two days, six 
weeks, and six months ranged from 0.70 to 0.87 for the total score, 0.49 to 0.78 for tangible, 0.60 
to 0.84 for appraisal, 0.54 to 0.74 for self-esteem, and 0.65 to 0.68 for belonging (Cohen, 1985). 
Medication adherence of RA drugs, such as prednisone, anti-tumor necrosis factor (TNF) 
drugs, and non-steroidal anti-inflammatory drugs (NSAIDs), was measured by using data 
collected from the Electronic Event Monitoring System (MEMS). MEMS allows the recording 
of percentage of prescribed administrations taken (dose adherence), percentage of days with the 
prescribed number of administrations (days adherence), and percentage of days with the 
prescribed number of administrations and optimal inter-dose intervals (on-time adherence). 
These recordings are made possible by the significant advances that have been made in the 
MEMS over the last few decades with current devices being small, microprocessor-based 
monitors (Dunbar-Jacob, Sereika, Rohay, & Burke, 1998). Each MEMS cap contains a battery-
powered microprocessor chip that records the date (month, day, year) and time (hour, minute, 
second) of when the monitor is activated (Dunbar-Jacob et al., 1998). The monitor is activated by 
opening and closing of a pill vial cap that contains the chip. The date and time of opening and 
closing the cap is recorded to the nearest second. Multiple opening and closing of the cap within 
just a few seconds, for example due to loose fitting caps or repeated manual opening and closing, 
create rapid firings that are automatically filtered and not included in the adherence data. The 
monitors are able to store data for several months or even over a year. Data can be downloaded 
directly onto a computer for review and analysis (Dunbar-Jacob et al., 1998). 
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MEMS does not record medication ingestion, although the activation of the monitor 
serves as an indicator of ingestion (Dunbar-Jacob et al., 1998). This limitation could potentially 
put the adherence measures at risk for inaccurate data, if the pill bottle was opened but the 
medication was not taken. However, the monitors record each access to the medication vial so 
the patients would need to exert considerable effort in order to actually trick the system. They 
would have to activate the medication monitor at each correct administration time. Since most of 
the patients’ poor adherence is due to forgetting, schedule disruptions, and other environmental 
interferences, the likelihood of the patients manipulating the MEMS in such a way is low 
(Dunbar-Jacob et al., 1998). 
Obtaining medication adherence measured objectively with MEMS reveals information 
that may otherwise not be possible with alternative means of adherence measures, such as self-
report questionnaires and diaries. Multiple studies have noted that adherence levels tend to be 
higher when assessed with self-report compared to objective measures such as MEMS. In one 
study examining the adherence to pilocarpine, nearly 90% of the sample reported 100% 
adherence with self-report. However, the eye drop monitor revealed just over 20% of the sample 
at 100% adherence (Dunbar-Jacob et al., 1998). Therefore, objective measures like MEMS are 
important in collecting accurate data for medication adherence. 
3.4 PROCEDURES 
In the parent study, subjects received the MEMS cap and were instructed to place the MEMS cap 
on their pill bottle containing the selected RA medication. They were informed to open the 
MEMS caps only to take the RA medication and to record in a diary any other openings or 
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missed doses. Subjects were instructed to use the MEMS cap for one month and then return it to 
the project office by mail. In addition, subjects received baseline questionnaires to complete and 
return by mail, which included a demographics questionnaire and the ISEL. 
3.5 STATISTICAL ANALYSES 
The MEMS data consist of the date and time of all activations of the MEMS cap. In the parent 
study, these values were then analyzed to derive the three measures of medication adherence. In 
the parent study, 30 days of MEMS data were collected. In order to calculate the baseline 
adherence, the first 7 days were dropped to allow the subjects to adapt to the use of the MEMS 
cap. Then the last day was dropped as well in order to prevent false readings due to an extra 
opening of the cap to turn it in or to avoid variations in data by turning it in before being due for 
a dose. Therefore, a total of 22 days of MEMS data were used in order to calculate the baseline 
adherence for this study. 
Data were analyzed using IBM® SPSS® Statistics version 23 (IBM Corp., Armonk, 
NY). The level of significance for two-sided hypothesis testing was set at .05 and 95% was used 
for confidence interval estimation. Data were first carefully screened for any anomalies (e.g., 
outliers, nonnormality, and missing data) and remedial measures applied as necessary (e.g., data 
transformations, imputation). Appropriate descriptive statistics based on the variable’s level of 
measurement and observed data distribution were used to summarize the sociodemographic 
characteristics of the sample, the ISEL total score and four subscale scores (tangible, appraisal, 
self-esteem, and belonging), and the three derived adherence measures (dose adherence, days 
adherence, and on-time adherence). 
 20 
Subjects with complete data in this sample were compared to those with missing data in 
the parent sample on all variables using parametric two-sample t-tests for continuous type (ratio 
or interval scaled) variables and Chi-square tests of independence for nominal scaled categorical 
variables. Nonparametric Mann-Whitney U-tests were used for group comparisons of 
nonnormally distributed continuous type variables and ordinal scaled categorical variables. 
Correlational analyses were used to examine the bivariate associations between the social 
support and adherence measures. Since the data were not normally distributed and normality 
could not be induced through data transformations, Spearman rank-order correlation coefficients 
were employed. Since some dose adherence values were greater than 100%, these values were 
folded so that the maximum dose adherence was 100%. For example, 110% was folded and 
became 90%. 
Initially, univariate linear regression was performed to study the bivariate associations 
between the adherence measures (dose adherence, days adherence, and on-time adherence) and 
the social support measures (ISEL total score and subscale scores). However, the bivariate 
scatterplots indicated nonnormality for all of the associations between social support and 
medication adherence measures. Thus, log based 10 transformations of the adherence measures 
were done to see if the transformed variables helped to correct the nonnormality of model 
residuals. However, the log transformation did not help to solve the nonnormality of model 
residuals. Thus, univariate binary logistic regression was employed to model the probability of 
being adherent using dichotomized medication adherence data. In addition, multivariate logistic 
regression models were employed to examine which of the four ISEL subscale scores best 
predicted each of the dichotomized medication adherence measures. In addition to point 
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estimates to summarize associations such as correlation and regression coefficients, the 
corresponding 95% confidence intervals were obtained. 
For the univariate and multivariate logistic regression models, the medication adherence 
variables were dichotomized into adherent and non-adherent categories due to the non-linearity 
of the data. For days adherence and on-time adherence, 80% was chosen as the adherence cut-off 
value with ≥80% classified as adherent and <80% classified as non-adherent. Since the value for 
dose adherence had the possibility of being over 100%, ≥80% and ≤120% were considered to be 
adherent and <80% or >120% was considered to be non-adherent. 
 22 
4.0  RESULTS 
4.1 SUBJECTS 
The 567 subjects were on average 59.2 (SD=11.9) years old with 13.4 (SD=2.5) years of 
education. The subjects were primarily women (80.2%), white (92.8%), married (65.6%), and 
employed (30.9%). 
4.2 DESCRIPTION OF SOCIAL SUPPORT AND MEDICATION ADHERENCE 
Table 1 describes the subjects’ social support and medication adherence. On average, the 
subjects had moderate to high social support in each of the four subscales, although the ranges 
were wide. Mean dose adherence was highest at 88.36% (SD=22.98) ranging from non-
adherence at 0% to over-adherence at 163.64%. Mean days adherence was intermediate at 
79.90% (SD=27.57, range 0 to 100), while mean on-time adherence was lowest at 58.80% 
(SD=34.42, range 0 to 95.45). 
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Table 1: Descriptive Statistics for Social Support and Medication Adherence (N=567) 
______________________________________________________________________________ 
 
Characteristic Mean (SD) Range 
______________________________________________________________________________ 
 
ISEL Scores   
   Tangible* 24.69 (4.55) 9.00 - 30.00 
   Appraisal* 23.13 (5.44) 3.00 - 30.00 
   Self-esteem* 20.07 (4.43) 4.00 - 30.00 
   Belonging* 23.16 (4.78) 4.00 - 30.00 
   Total** 91.05 (16.67) 34.00 - 120.00 
Medication Adherence   
   Dose Adherence 88.36 (22.98) 0.00 - 163.64 
   Days Adherence 79.90 (27.57) 0.00 - 100.00 
   On-time Adherence 58.80 (34.42) 0.00 - 95.45 
______________________________________________________________________________ 
 
Note. ISEL=Interpersonal Support Evaluation List. 
*Possible range 0-30. 
**Possible range 0-120. 
4.3 BIVARIATE CORRELATIONAL ANALYSES 
Spearman rank-order correlations were used to examine the bivariate associations between the 
adherence measures and the ISEL total score. As shown in Table 2, no statistically significant 
correlations were found between social support and medication adherence. 
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Table 2. Spearman Rank-Order Correlations between Social Support and Medication Adherence 
(N=567) 
______________________________________________________________________________ 
 
ISEL Scores Medication Adherence 
rs (p) 
______________________________________________________________ 
 
Dose Adherence Dose Adherence 
Folded 
Days Adherence On-time 
Adherence 
______________________________________________________________________________ 
 
Tangible .050 (.232) .067 (.110) .064 (.128) .043 (.302) 
Appraisal .023 (.587) .041 (.335) .057 (.175) .009 (.827) 
Self-Esteem -.050 (.234) -.029 (.493) -.016 (.713) -.030 (.472) 
Belonging -.006 (.884) -.007 (.875) .013 (.762) .016 (.709) 
Total .008 (.850) .019 (.651) .034 (.420) .008 (.848) 
______________________________________________________________________________ 
Note. ISEL=Interpersonal Support Evaluation List. 
4.4 REGRESSION ANALYSES 
Using univariate logistic regression analyses, none of the dichotomized adherence measures were 
significantly associated with the social support measures (Tables 3, 4, and 5). Although no 
significant associations were found with univariate logistic regression analyses, multivariate 
logistic regression analyses were used to examine which of the four ISEL subscale scores best 
predicted each of the dichotomized adherence measures (Table 6, 7, and 8). No significant 
predictor was found for days adherence; however, there were significant predictors for the other 
two adherence measures. For dose adherence, tangible social support was a significant predictor 
(OR=1.082, 95% CI=1.008 - 1.162). For on-time adherence, self-esteem social support was a 
significant predictor (OR=0.942, 95% CI=0.893 - 0.994). 
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Table 3. Univariate Logistic Regression of Social Support Predicting of Being Adherent based on 
Dose Adherence (N=567) 
___________________________________________________________________________ 
 
ISEL Scores Dose Adherence 
___________________ 
 
Univariate Logistic Regression Results 
_________________________________________ 
 
 <80% or 
>120% 
Mean (SD) 
n=105 
≥80% and 
≤120% 
Mean (SD) 
n=462 
Odds Ratio 95% CI Wald Test Statistic 
X2 (p) 
___________________________________________________________________________ 
 
Tangible 
 
 
24.27 
(4.73) 
24.78 
(4.50) 
1.024 0.979 - 1.072 1.054 (.305) 
Appraisal 
 
 
23.30 
(5.68) 
23.09 
(5.39) 
0.993 0.955 - 1.033 0.120 (.729) 
Self-esteem 
 
 
20.61 
(4.98) 
19.95 
(4.30) 
0.966 0.920 - 1.015 1.894 (.169) 
Belonging 
 
 
23.28 
(5.59) 
23.13 
(4.59) 
0.994 0.950 - 1.039 0.078 (.780) 
Total 
 
91.46 
(18.95) 
90.95 
(16.13) 
0.998 0.985 - 1.011 0.081 (.776) 
___________________________________________________________________________ 
 
Note. CI=Confidence Interval; ISEL=Interpersonal Support Evaluation List. 
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Table 4. Univariate Logistic Regression of Social Support Predicting of Being Adherent based on 
Days Adherence (N=567) 
___________________________________________________________________________ 
 
ISEL Scores Days Adherence 
___________________ 
 
Univariate Logistic Regression Results 
_________________________________________ 
 
 <80% 
Mean (SD) 
n=170 
≥80% 
Mean (SD) 
n=397 
Odds Ratio 95% CI Wald Test Statistic 
X2 (p) 
___________________________________________________________________________ 
 
Tangible 
 
 
24.47 
(4.63) 
24.78 
(4.51) 
1.015 0.976 - 1.055 0.549 (.459) 
Appraisal 
 
 
22.90 
(5.56) 
23.23 
(5.39) 
1.011 0.979 - 1.045 0.449 (.503) 
Self-esteem 
 
 
20.26 
(4.83) 
19.99 
(4.26) 
0.986 0.947 - 1.028 0.428 (.513) 
Belonging 
 
 
23.01 
(5.25) 
23.22 
(4.58) 
1.009 0.972 - 1.048 0.228 (.633) 
Total 
 
90.63 
(17.96) 
91.22 
(16.11) 
1.002 0.991 - 1.013 0.150 (.698) 
___________________________________________________________________________ 
 
Note. CI=Confidence Interval; ISEL=Interpersonal Support Evaluation List. 
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Table 5. Univariate Logistic Regression of Social Support Predicting of Being Adherent based on 
On-time Adherence (N=567) 
___________________________________________________________________________ 
 
ISEL Scores On-time Adherence 
___________________ 
 
Univariate Logistic Regression Results 
_________________________________________ 
 
 <80% 
Mean (SD) 
n=340 
≥80% 
Mean (SD) 
n=227 
Odds Ratio 95% CI Wald Test Statistic 
X2 (p) 
___________________________________________________________________________ 
 
Tangible 
 
 
24.54 
(4.66) 
24.90 
(4.38) 
1.017 0.980 - 1.056 0.829 (.363) 
Appraisal 
 
 
23.07 
(5.40) 
23.22 
(5.52) 
1.005 0.975 - 1.037 0.114 (.736) 
Self-esteem 
 
 
20.23 
(4.47) 
19.84 
(4.39) 
0.981 0.944 - 1.019 1.024 (.312) 
Belonging 
 
 
23.03 
(4.80) 
23.35 
(4.77) 
1.014 0.979 - 1.051 0.618 (.432) 
Total 
 
90.86 
(16.79) 
91.32 
(16.52) 
1.002 0.992 - 1.012 0.105 (.746) 
___________________________________________________________________________ 
 
Note. CI=Confidence Interval; ISEL=Interpersonal Support Evaluation List. 
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Table 6. Multivariate Logistic Regression of Social Support Predicting of Being Adherent based on 
Dose Adherence (N=567) 
_____________________________________________________ 
 
ISEL Scores Multivariate Logistic Regression Results 
_________________________________________ 
 
 Adjusted 
Odds Ratio 
95% CI Wald Test Statistic 
X2 (p) 
_____________________________________________________ 
 
Tangible 1.082 1.008 - 1.162 4.723 (.030) 
Appraisal 0.987 0.926 - 1.051 0.175 (.675) 
Self-esteem 0.936 0.874 - 1.003 3.561 (.059) 
Belonging 0.990 0.909 - 1.078 0.054 (.817) 
_____________________________________________________ 
 
Note. CI=Confidence Interval; ISEL=Interpersonal Support Evaluation List. 
 
 
 
Table 7. Multivariate Logistic Regression of Social Support Predicting of Being Adherent based on 
Days Adherence (N=567) 
_____________________________________________________ 
 
ISEL Scores Multivariate Logistic Regression Results 
_________________________________________ 
 
 Adjusted 
Odds Ratio 
95% CI Wald Test Statistic 
X2 (p) 
_____________________________________________________ 
 
Tangible 1.021 0.961 - 1.085 0.470 (.493) 
Appraisal 1.014 0.963 - 1.068 0.278 (.598) 
Self-esteem 0.957 0.904 - 1.014 2.236 (.135) 
Belonging 1.010 0.940 - 1.084 0.069 (.793) 
_____________________________________________________ 
 
Note. CI=Confidence Interval; ISEL=Interpersonal Support Evaluation List. 
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Table 8. Multivariate Logistic Regression of Social Support Predicting of Being Adherent based on 
On-time Adherence (N=567) 
_____________________________________________________ 
 
ISEL Scores Multivariate Logistic Regression Results 
_________________________________________ 
 
 Adjusted Odds Ratio 95% CI Wald Test Statistic X2 (p) 
_____________________________________________________ 
 
Tangible 1.026 0.968 - 1.087 0.746 (.388) 
Appraisal 0.993 0.945 - 1.044 0.072 (.788) 
Self-esteem 0.942 0.893 - 0.994 4.714 (.030) 
Belonging 1.041 0.972 - 1.114 1.332 (.248) 
_____________________________________________________ 
 
Note. CI=Confidence Interval; ISEL=Interpersonal Support Evaluation List. 
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5.0  DISCUSSION 
The present study was conducted to determine the association between social support and 
medication adherence in adults treated for RA. This study showed no significant bivariate 
association between the adherence measures and the ISEL social support measures using 
correlational analyses or univariate logistic regression analyses. However, when all four ISEL 
subscales were examined with each of the adherence measures, significance was found in two 
subscales. For every one point increase in tangible support (based on the ISEL tangible 
subscale), the odds of being adherent to RA medications based on dose adherence at baseline are 
estimated to increase 1.082 times, controlling for the other ISEL subscale measures. Tangible 
support is determined by statements such as, “If I needed help fixing an appliance or repairing 
my car, there is someone who would help me.” In addition, the odds of being adherent to RA 
medications based on on-time adherence at baseline are estimated to be 0.942 less with a one 
unit increase in self-esteem support (based on the ISEL self-esteem subscale), controlling for the 
other ISEL subscale measures. Self-esteem was measured with statements such as, “I am as good 
at doing things as most other people are.” These results may be due to controlling for the effect 
of other social support subscale measures that may be related to alternate variables affecting the 
associations between the medication adherence and social support. 
Although most of the previous studies that examined associations between social support 
and medication adherence did not have significant findings, the study by Chen and Wang (2007) 
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found a positive association, similar to this present study. All of the previous studies had small 
samples and measured adherence through self-report or pill count, which are prone to recall bias 
and pill dumping, respectively. For this study, a large sample was used, medication adherence to 
RA drugs was measured objectively through the use of MEMS, and social support was measured 
by using the valid and reliable ISEL. Therefore, the results obtained through this study are more 
meaningful than past studies. 
One of the limitations of this study is that although the ISEL is a valid and reliable social 
support measure, it is not specific to medication adherence regimens. Perhaps a social support 
measure that is more relevant to medication self-management and adherence would be able to 
demonstrate more accurate associations between social support and adherence. Second, the 
correlational design of this study does not permit causal inferences to be made between social 
support and medication adherence. 
Future studies could be designed to explore the roles of tangible and self-esteem social 
support on medication adherence. A better understanding of these relationships may help to 
inform interventions intended to mobilize social support. 
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